scopus biopharma inc - SCPS

SCPS

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 200.00

Last Updated:

Jan 14, 2026, 11:29 AM EDT

Company Overview: scopus biopharma inc - SCPS

SCPS Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.01

Market Cap

$0.00

Shares Outstanding

42.08M

Public Float

32.87M

Beta

31.27

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.24

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.03K

 

SCPS Performance

1 Week
 
0.00%
 
1 Month
 
0.00%
 
3 Months
 
-60.00%
 
1 Year
 
33.33%
 
5 Years
 
N/A
 

SCPS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About scopus biopharma inc - SCPS

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company was founded on April 18, 2017 and is headquartered in New York, NY.

SCPS At a Glance

Scopus Biopharma, Inc.
420 Lexington Avenue
New York, New York 10170
Phone 1-212-479-2513 Revenue 0.00
Industry Pharmaceuticals: Other Net Income -11,609,827.00
Sector Health Technology Employees 13
Fiscal Year-end 12 / 2023
View SEC Filings

SCPS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.122
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

SCPS Efficiency

Revenue/Employee N/A
Income Per Employee -893,063.615
Receivables Turnover N/A
Total Asset Turnover N/A

SCPS Liquidity

Current Ratio 0.052
Quick Ratio 0.052
Cash Ratio 0.017

SCPS Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -269.559
Return on Equity N/A
Return on Total Capital 177.782
Return on Invested Capital N/A

SCPS Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Scopus Biopharma Inc - SCPS

Collapse All in section
All values USD millions. 2019 2020 2021 2022 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
664 1.44K 1.50K 1.73K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
664 1.44K 1.50K 1.73K
Depreciation
664 1.44K 1.50K 1.73K
Amortization of Intangibles
- - - -
-
COGS Growth
- +116.87% +4.17% +15.20%
Gross Income
(664) (1.44K) (1.50K) (1.73K)
Gross Income Growth
- -116.87% -4.17% -15.20%
Gross Profit Margin
- - - -
-
2019 2020 2021 2022 5-year trend
SG&A Expense
2.69M 10.15M 27.63M 11.71M
Research & Development
463.11K 7.42M 15.02M 2.68M
Other SG&A
2.23M 2.73M 12.61M 9.03M
SGA Growth
+292.04% +277.59% +172.13% -57.61%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (1.46M)
-
EBIT after Unusual Expense
(2.69M) (10.16M) (26.18M) (11.71M)
Non Operating Income/Expense
- - - -
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 706.45K 774.68K
-
Interest Expense Growth
- - +9.66% -100.00%
-
Gross Interest Expense
- - 706.45K 774.68K
-
Interest Capitalized
- - - -
-
Pretax Income
(2.69M) (10.86M) (26.95M) (11.71M)
Pretax Income Growth
-292.14% -303.81% -148.14% +56.54%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- (839.29K) (1.77M) (4.12M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- 772.83K 1.73M 4.08M
Income Tax - Deferred - Foreign
- 66.46K 37.88K 38.98K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(2.69M) (10.86M) (26.95M) (11.71M)
Minority Interest Expense
- - - (105.05K)
-
Net Income
(2.69M) (10.86M) (26.95M) (11.61M)
Net Income Growth
-292.14% -303.81% -148.14% +56.93%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(2.69M) (10.86M) (26.95M) (11.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(2.69M) (10.86M) (26.95M) (11.61M)
EPS (Basic)
- - -0.8155 -1.5623
-
EPS (Basic) Growth
- - - -91.58%
-
Basic Shares Outstanding
- - 13.36M 17.25M
-
EPS (Diluted)
- - -0.8155 -1.5623
-
EPS (Diluted) Growth
- - - -91.58%
-
Diluted Shares Outstanding
- - 13.36M 17.25M
-
EBITDA
(2.69M) (10.15M) (27.63M) (11.71M)
EBITDA Growth
-292.05% -277.59% -172.13% +57.61%
EBITDA Margin
- - - -
-

Scopus Biopharma Inc in the News